There is a pressing need for methods delivering therapeutic macromolecules to their intracellular targets at low nanomolar concentrations without endosomal entrapment. Certain viruses and bacterial toxins exploit lipid raft-mediated endocytosis to deliver macromolecules in their functional form without degradation, which we set out to mimic in our approach. These proteins of viral and bacterial origins trigger the desired intracellular delivery by binding to gangliosides at the lipid raft entry points.
We discovered a pentapeptide sequence that specifically captures the lipid raft marker ganglioside GM1. Thus, it triggers endocytosis on various human live cell lines. The cargo-loaded endosomes show limited fusion with lysosomes. Several immunoglobulin G complexes were successfully delivered into live cells at extracellular concentrations ranging from 20 to 160 nM. The antibodies’ molecular recognition regions remained functional, and the escape of the functional cargo protein to the cytosol was observed without any additional endosomal escape sequence. The carrier tag was not toxic even in the high micromolar region.
Company Details
- Employees
- 4
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://viabrane.com
- Keywords
- Bio-Science Kft./Ltd. - Hungary.
Viabrane Inc. Questions
Viabrane Inc.'s website is https://viabrane.com
Viabrane Inc.'s LinkedIn profile is https://www.linkedin.com/company/viabrane-inc
Viabrane Inc. has
4 employees.
View email and phone details for 4
employees at Viabrane Inc..
Viabrane Inc.'s industry is
Biotechnology Research
Viabrane Inc.'s top competitors are
Hlbs Network,
Shopever.hu,
Biotech Hungary Ltd.,
Xpamac Inc.,
Xellia Pharmaceuticals,
Bio-Science Kft./ltd. - Hungary,
University Of Maryland Medical Center,
Gpa Venture Partners,
Mnml.ai,
Ceva Sante Animale.
Viabrane Inc.'s categories are Biotechnology Research
Viabrane Inc.'s founding year is 2024
